2026 Shilajit Research Roundup: 5 New Studies

Last reviewed: May 20, 2026 · By Dr. Ekta Gupta · Evidence tier labels apply on every claim (see our editorial policy)

If you searched for the latest shilajit research in 2026 hoping for proof that this Himalayan resin is a miracle cure, this roundup will disappoint you — and that is exactly why it is worth reading. None of the five studies below shows that shilajit cures any disease, replaces a prescribed medication, or works the same way in everyone. Most are early-stage: small human pilots, animal experiments, and chemistry papers. What they do offer is the most honest snapshot yet of where the evidence actually stands, including two findings that should make every shilajit buyer more cautious, not less.

We pulled these directly from PubMed, read the full abstracts, and summarised them with their limitations attached. Where a study was funded by a supplement company or could not isolate shilajit's effect, we say so. Here is what the 2026 shilajit research landscape really looks like.

How to read "new shilajit research" without fooling yourself

Before the studies, a quick filter. Nutrition headlines collapse the difference between a 25-person pilot and a 10,000-person trial, but that difference is everything. As you read, weight each finding by its evidence tier:

• [RCT] — randomised, placebo-controlled human trials. The gold standard, but still small for shilajit.
• [Human pilot] — early human data, often without a placebo group. Hypothesis-generating, not conclusive.
• [Animal model] — rat or cell studies. Useful for mechanism, but doses and biology do not translate directly to people.
• [Analytical] — chemistry papers measuring what is actually in the resin. Quietly the most useful tier for buyers.

A genuine benefit also has to survive replication in larger groups. The studies below are signposts, not destinations. If you want the deeper background on why resin potency varies so much, our guide to fulvic acid in shilajit pairs well with the chemistry papers in this roundup.

Study 1 — Shilajit resin and physical performance (28-day human pilot)

The most directly relevant 2026 study for anyone taking shilajit resin tested the traditional resin form rather than a standardised extract. In a 28-day, open-label pilot, 25 healthy, moderately active men aged 21–55 took 500 mg of shilajit resin per day (250 mg twice daily) Yadav 2026 (Cureus). [Human pilot]

The within-group changes after four weeks were notable: one-rep-max leg-press strength rose 12.9%, muscle endurance 12.3%, and grip strength 5.7%, while fatigue scores fell 32.4% and perceived exertion fell 23.6%. C-reactive protein, an inflammation marker, dropped 25.4%, lean body mass rose 1.5%, and body fat fell 2.3%. No serious adverse events were reported, and liver, kidney, and blood parameters stayed within normal limits.

That sounds impressive, so here is the honest framing the authors themselves insist on. This was open-label and single-arm — there was no placebo group, so part of the improvement could be expectation, training familiarity, or the structure of being monitored. The sample was small (25), male-only, and the study was conducted by a supplement company's research team. The authors explicitly call for larger, randomised, placebo-controlled trials before drawing firm conclusions. Read it as encouraging early evidence that resin is worth studying properly — not as proof it will add 13% to your leg press. If performance is your goal, our evidence review for athletes and runners covers the wider literature.

Study 2 — Shilajit inside a cardiometabolic RCT

The highest-quality design in this roundup is a randomised, double-blind, placebo-controlled trial from Texas A&M University, published in 2025. Across 12 weeks, 166 sedentary adults with at least two metabolic-syndrome risk factors began an exercise-and-diet programme and were randomised to placebo or to supplements containing chromium, Phyllanthus emblica (amla), and shilajit; 109 completed it Martinez 2025 (Nutrients). [RCT]

Compared with placebo, the supplement groups showed some evidence of improved arterial stiffness, blood-vessel function, insulin sensitivity, blood lipids, and body composition, with the higher dose performing more consistently. So why the cautious language? Because shilajit was a minor component — just 6–12 mg per dose, alongside far larger amounts of chromium and amla — so the trial cannot tell us how much, if any, of the benefit came from shilajit itself. The study was also industry-funded. It is a legitimate, well-run RCT, but it is a trial of a combination formula, not of shilajit alone. Anyone citing it as "an RCT proving shilajit improves metabolic health" is overreaching. For the standalone picture, see our science-backed look at shilajit and weight loss.

Study 3 — Shilajit and bone regeneration (animal model)

A 2025 in-vivo experiment looked at whether shilajit could support bone healing. Researchers created standardised tibial defects in 28 rats, filled them with a bone graft, and gave high- or low-dose shilajit for the first four days Guler 2025 (Life). [Animal model]

After four weeks, the high-dose group showed significantly higher antioxidant status, lower oxidative stress, reduced inflammatory TNF-α, and the greatest percentage of new bone area (about 78%). The proposed mechanism — shilajit's antioxidant and anti-inflammatory activity supporting the bone-healing environment — is biologically plausible. [Mechanism] But this is a rat study using injected shilajit at a localised surgical site; it does not show that swallowing resin strengthens human bones or speeds fracture recovery. It is a reason to run human trials, nothing more. Our overview of shilajit and bone health puts this in context with the mineral-absorption evidence.

Study 4 — What is actually in shilajit: composition across five regions

This 2026 analytical paper is unglamorous but genuinely useful for buyers. Using HPLC-MS/MS, chemists quantified nine plant-derived phenolic acids in 11 shilajit samples from Iran, India, Nepal, Russia, and Kyrgyzstan Kamgar 2026 (Sci Rep). [Analytical]

Two takeaways matter. First, the antioxidant phenolic-acid content varied dramatically by region — gallic acid alone ranged into the thousands of micrograms per gram in some samples. Second, that variation is direct chemical evidence that "shilajit" is not one standardised substance; where it forms changes what is in it. The practical implication is blunt: a product's origin and a current lab report tell you far more than the word "Himalayan" on a label. This is the science behind why we publish per-batch composition data, and why our explainer on how authentic shilajit is purified emphasises sourcing chain over marketing claims.

Study 5 — The purity problem: heavy metals in shilajit supplements

The most important study here for your safety is also the least flattering to the category. Researchers measured thallium — a highly toxic heavy metal — in raw shilajit and in commercial shilajit supplements from several regions Kamgar 2025 (BMC Chem). [Analytical]

Thallium turned up in both raw resin and finished supplements, reaching up to roughly 0.5 µg/g in products tested. The detail that should change how you shop: in some cases the supplements contained more thallium than the crude shilajit, suggesting processing and handling can add contamination rather than remove it. The authors call for regular monitoring and standardised testing to keep products within safe limits. This is not a reason to fear all shilajit — it is the single best argument for buying only resin with a current, third-party, per-batch heavy-metal certificate of analysis. Our 2026 India counterfeit report goes deeper on how adulterated and untested resin reaches the market.

What is still missing from the shilajit evidence

An honest roundup has to name the gaps, because they are large. Despite the 2026 activity, the shilajit research base still has four structural weaknesses that should temper any marketing you read:

• No large standalone RCT. The strongest design in this batch tested shilajit only as a minor part of a combination formula. There is still no big, long, placebo-controlled trial of resin on its own — the kind of study that would actually settle the benefit question.
• Tiny, narrow samples. The headline resin pilot enrolled 25 men. Women, older adults, and people with chronic conditions are barely represented, so the findings cannot be generalised to "everyone."
• No standardised dose or potency. Studies use different forms, doses, and fulvic-acid concentrations, and — as the chemistry papers show — the raw material itself varies by region. That makes results hard to compare and harder to translate into a label instruction.
• Thin long-term safety data. Most trials run weeks, not years. Combined with the documented contamination risk, that is a strong argument for cycling, sensible dosing, and verified purity rather than indefinite high-dose use.

None of this means shilajit "does not work." It means the science is early, and the responsible reader holds benefit claims loosely while taking the quality findings seriously. If you are deciding how to use resin day to day, our shilajit cycling protocol reflects this caution.

What the 2026 shilajit research means for you

Pulling the five together, a measured reading looks like this:

• The benefit signals are early but real-ish. Resin shows promising performance and recovery effects in a small pilot, and shilajit appears in a metabolic-health RCT — but neither is conclusive on its own.
• Mechanisms are consistent. Antioxidant and anti-inflammatory activity recurs across the human, animal, and chemistry papers, which is what you want to see before larger trials.
• Quality is not optional. Two of the five studies are essentially about what is in the jar — composition varies by origin, and contamination is a documented risk. Testing is the difference between a mineral supplement and a heavy-metal exposure.

In other words, the 2026 evidence is less a green light for shilajit's benefits and more a flashing sign that which shilajit you take matters as much as whether you take it.

Frequently Asked Questions

Is there any 2026 human evidence for shilajit, or only animal studies?

Both. A 2026 open-label human pilot tested shilajit resin for physical performance, and a 2025 randomised controlled trial included shilajit in a metabolic-health formula. However, the pilot lacked a placebo group and the RCT used only 6–12 mg of shilajit within a larger blend, so neither is definitive proof of shilajit's standalone effects.

Does the new research prove shilajit boosts strength or testosterone?

No. The 2026 resin pilot reported strength and endurance improvements over 28 days, but because it was open-label and single-arm with only 25 men, it cannot rule out placebo and training effects. It supports running larger randomised trials rather than confirming the benefit.

What did the 2026 studies say about shilajit purity?

A 2025 analytical study found thallium, a toxic heavy metal, in both raw shilajit and finished supplements — sometimes at higher levels in the supplements than the raw material. This is the strongest reason to choose resin with a current third-party, per-batch heavy-metal certificate of analysis.

Why does shilajit composition vary so much between brands?

A 2026 chemistry paper analysing samples from five countries found that antioxidant phenolic-acid content varied dramatically by region. Because shilajit forms differently depending on location and source material, two "Himalayan" products can differ substantially. Origin transparency and lab testing matter more than the label.

Can I rely on the metabolic-health RCT to choose shilajit?

Only loosely. It was a well-designed randomised trial, but shilajit was a small part of a chromium-and-amla formula, so the benefits cannot be attributed to shilajit alone. Treat it as supporting evidence for the combination, not proof of shilajit by itself.

Are these studies a reason to start or stop taking shilajit?

Neither on their own. They suggest modest, plausible benefits and a clear quality risk. If you take shilajit, the practical action item is to verify your product's third-party testing, not to change your dose based on early-stage research.

Should I talk to a doctor before using shilajit?

Yes, especially if you are pregnant or breastfeeding, manage diabetes, take blood-pressure or hormone medication, or have kidney or liver conditions. Shilajit is a mineral-rich supplement, and a clinician can advise whether it is appropriate alongside your medications and health status.

The Bottom Line

The 2026 shilajit research is genuinely interesting and genuinely preliminary. Early human and animal data hint at benefits for performance, recovery, and metabolic markers through antioxidant and anti-inflammatory pathways, but no study here proves shilajit cures or treats disease. The most actionable findings are the chemistry papers: composition varies by origin and contamination is a documented risk, so the smartest response to this research is not a bigger dose — it is insisting on lab-tested, third-party-verified resin.

References: Yadav 2026 (Cureus); Martinez 2025 (Nutrients); Guler 2025 (Life); Kamgar 2026 (Scientific Reports); Kamgar 2025 (BMC Chemistry).